Merus and Halozyme partner on subcutaneous petosemtamab formulation Nov 17, 2025 07:00AM
Merus and Halozyme partner on subcutaneous petosemtamab formulation Nov 17, 2025 07:00AM
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab Nov 17, 2025 07:00AM
Merus N.V. (MRUS): Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma Feb 18, 2025 08:01AM
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma Feb 18, 2025 08:00AM
View Older Stories

Jul 1, 2024 08:00AM Merus N.V. (MRUS) Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
Jul 1, 2024 08:00AM Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
May 28, 2024 07:04AM Merus' (MRUS) Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
May 28, 2024 07:00AM Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
May 24, 2024 07:38AM Merus (MRUS) Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO Annual Meeting
May 23, 2024 05:00PM Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
May 23, 2024 05:00PM Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
May 13, 2024 08:03AM Merus N.V. (MRUS) Reports Petosemtamab Granted FDA Breakthrough Therapy Designation
May 13, 2024 08:00AM Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
Mar 6, 2024 08:01AM Gilead Sciences (GILD), Merus (MRUS) Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
Mar 6, 2024 08:00AM Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
Jan 31, 2024 08:00AM Merus to Participate in Upcoming Investor Conferences
Dec 2, 2023 08:40PM Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023
Nov 26, 2023 11:05AM Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023
Nov 2, 2023 04:12PM Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
Nov 1, 2023 08:00AM Merus to Participate in Upcoming Investor Conferences
Oct 23, 2023 07:30AM Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer
Oct 15, 2023 07:58PM Merus Announces Business Update Conference Call
Oct 6, 2023 09:32AM Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
Aug 31, 2023 08:00AM Merus to Participate in Upcoming Investor Conferences
Aug 7, 2023 04:26PM Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
Jul 28, 2023 08:00AM Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 202
Jul 5, 2023 04:01PM Merus N.V. (MRUS) Announces Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by FDA
Jul 5, 2023 04:01PM Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
Jul 5, 2023 04:01PM Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
Jun 29, 2023 04:30PM Merus N.V. (MRUS) Reports Zenocutuzumab granted Breakthrough Therapy Designation by FDA
Jun 29, 2023 04:30PM Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
Jun 29, 2023 04:30PM Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
Jun 15, 2023 07:49AM Merus N.V. (MRUS) Appoints Greg Perry as CFO
Jun 15, 2023 07:47AM Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer
May 31, 2023 08:00AM Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023
May 4, 2023 04:25PM Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update
Apr 17, 2023 10:15AM Merus N.V. (MRUS) Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma
Apr 17, 2023 10:15AM Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
Apr 17, 2023 10:15AM Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
Apr 14, 2023 11:12AM Merus N.V. (MRUS) Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR
Apr 14, 2023 11:11AM Merus N.V. (MRUS) Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR
Apr 14, 2023 11:10AM Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023
Apr 14, 2023 11:10AM Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
Apr 14, 2023 11:10AM Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
Apr 14, 2023 11:10AM Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023
Mar 14, 2023 04:30PM Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
Mar 14, 2023 04:30PM Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023
Mar 14, 2023 04:30PM Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
Mar 14, 2023 04:30PM Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023
Feb 28, 2023 04:25PM Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update
Feb 28, 2023 04:25PM Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update
Feb 1, 2023 08:00AM Merus to Participate in Upcoming Investor Conferences
Feb 1, 2023 08:00AM Merus to Participate in Upcoming Investor Conferences
Jan 9, 2023 06:05AM CORRECTING and REPLACING --Merus Provides 2023 Outlook
View Older Stories